Overview

A Phase III Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.
Phase:
Phase 3
Details
Lead Sponsor:
Medytox Korea
Treatments:
Botulinum Toxins, Type A